DNA methyltransferases 1 and 3B are required for hepatitis C virus infection in cell culture

Virology

Volumn 441, Issue 1, 2013, Pages 57-65

  Chen, Chao ^a   Pan, Dan ^a   Deng, A Mei ^a   Huang, Fang ^a   Sun, Bin Lian ^a   Yang, Rong Ge ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

5 Aza C; 5 Aza dC; DNMT1; DNMT3A; DNMT3B; Hepatitis C virus; Infection; Replication

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE INHIBITOR; SHORT HAIRPIN RNA; VIRUS RNA;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG TARGETING; GENE SILENCING; HEPATITIS C; HEPATITIS C VIRUS; HOST; INTERNAL RIBOSOME ENTRY SITE; LENTIVIRINAE; LIFE CYCLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; RNA REPLICATION; RNA TRANSLATION; VIRUS ENTRY; VIRUS GENOME; VIRUS REPLICATION;

CELL LINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; GENE KNOCKDOWN TECHNIQUES; HEPACIVIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRUS CULTIVATION; VIRUS REPLICATION;

HEPATITIS C VIRUS; LENTIVIRUS;

EID: 84877603505     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.03.005     Document Type: Article

References (41)

1. Arora P., Kim E.O., Jung J.K., Jang K.L. Hepatitis C virus core protein downregulates E-cadherin expression via activation of DNA methyltransferase 1 and 3b. Cancer Lett. 2008, 261(2):244-252.
2. Bartosch B., Dubuisson J., Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 2003, 197(5):633-642.
3. Benegiamo G., Vinciguerra M., Mazzoccoli G., Piepoli A., Andriulli A., Pazienza V. DNA methyltransferases 1 and 3b expression in Huh-7 cells expressing HCV core protein of different genotypes. Dig. Dis. Sci. 2012, 57(6):1598-1603.
4. Bestor T.H. The DNA methyltransferases of mammals. Hum. Mol. Genet. 2000, 9(16):2395-2402.
5. Bouchard J., Walker M.C., Leclerc J.M., Lapointe N., Beaulieu R., Thibodeau L. 5-azacytidine and 5-azadeoxycytidine inhibit human immunodeficiency virus type 1 replication in vitro. Antimicrob. Agents Chemother. 1990, 34(2):206-209.
6. Chen C., Qiu H., Gong J., Liu Q., Xiao H., Chen X.W., Sun B.L., Yang R.G. (-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus. Arch. Virol. 2012, 157(7):1301-1312.
7. Ciesek S., Steinmann E., Wedemeyer H., Manns M.P., Neyts J., Tautz N., Madan V., Bartenschlager R., von Hahn T., Pietschmann T. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 2009, 50(5):1638-1645.
8. Dapp M.J., Clouser C.L., Patterson S., Mansky L.M. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J. Virol. 2009, 83(22):11950-11958.
9. Fan H., Zhao Z.J., Cheng J., Su X.W., Wu Q.X., Shan Y.F. Overexpression of DNA methyltransferase 1 and its biological significance in primary hepatocellular carcinoma. World J. Gastroenterol. 2009, 15(16):2020-2026.
10. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4(2):143-153.
11. Georgel P., Schuster C., Zeisel M.B., Stoll-Keller F., Berg T., Bahram S., Baumert T.F. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol. Med. 2010, 16(6):277-286.
12. Ghoshal K., Datta J., Majumder S., Bai S., Kutay H., Motiwala T., Jacob S.T. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol. Cell Biol. 2005, 25(11):4727-4741.
13. Han Q., Xu C., Wu C., Zhu W., Yang R., Chen X. Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus. Virus Res. 2009, 145(1):63-73.
14. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36(5 Suppl. 1):S21-S29.
15. Issa J.P. DNA methylation as a therapeutic target in cancer. Clin. Cancer Res. 2007, 13(6):1634-1637.
16. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128(4):683-692.
17. Jurkowska R.Z., Jurkowski T.P., Jeltsch A. Structure and function of mammalian DNA methyltransferases. Chembiochem 2011, 12(2):206-222.
18. Kato T., Date T., Murayama A., Morikawa K., Akazawa D., Wakita T. Cell culture and infection system for hepatitis C virus. Nat. Protoc. 2006, 1(5):2334-2339.
19. Kaul A., Stauffer S., Berger C., Pertel T., Schmitt J., Kallis S., Zayas M., Lohmann V., Luban J., Bartenschlager R. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. 2009, 5(8):e1000546.
20. Leu Y.W., Rahmatpanah F., Shi H., Wei S.H., Liu J.C., Yan P.S., Huang T.H. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Cancer Res. 2003, 63(19):6110-6115.
21. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285(5424):110-113.
22. Lopez-Serra P., Esteller M. DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 2011.
23. Ma S., Boerner J.E., TiongYip C., Weidmann B., Ryder N.S., Cooreman M.P., Lin K. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob. Agents Chemother. 2006, 50(9):2976-2982.
24. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 2007, 5(6):453-463.
25. Naka K., Abe K., Takemoto K., Dansako H., Ikeda M., Shimotohno K., Kato N. Epigenetic silencing of interferon-inducible genes is implicated in interferon resistance of hepatitis C virus replicon-harboring cells. J. Hepatol. 2006, 44(5):869-878.
26. Nishida N., Nagasaka T., Nishimura T., Ikai I., Boland C.R., Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008, 47(3):908-918.
27. Paeshuyse J., Kaul A., De Clercq E., Rosenwirth B., Dumont J.M., Scalfaro P., Bartenschlager R., Neyts J. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006, 43(4):761-770.
28. Park S.H., Lim J.S., Lim S.Y., Tiwari I., Jang K.L. Hepatitis C virus Core protein stimulates cell growth by down-regulating p16 expression via DNA methylation. Cancer Lett. 2011, 310(1):61-68.
29. Poenisch M., Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis. 2011, 30(4):333-347.
30. Portela A., Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 2010, 28(10):1057-1068.
31. Rhee I., Bachman K.E., Park B.H., Jair K.W., Yen R.W., Schuebel K.E., Cui H., Feinberg A.P., Lengauer C., Kinzler K.W., Baylin S.B., Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002, 416(6880):552-556.
32. Robert M.F., Morin S., Beaulieu N., Gauthier F., Chute I.C., Barsalou A., MacLeod A.R. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. 2003, 33(1):61-65.
33. Saito Y., Kanai Y., Nakagawa T., Sakamoto M., Saito H., Ishii H., Hirohashi S. Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int. J. Cancer 2003, 105(4):527-532.
34. Santi D.V., Norment A., Garrett C.E. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc. Natl. Acad. Sci. USA 1984, 81(22):6993-6997.
35. Schrump D.S., Fischette M.R., Nguyen D.M., Zhao M., Li X., Kunst T.F., Hancox A., Hong J.A., Chen G.A., Pishchik V., Figg W.D., Murgo A.J., Steinberg S.M. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin. Cancer Res. 2006, 12(19):5777-5785.
36. She Y., Liao Q., Chen X., Ye L., Wu Z. Hepatitis C virus (HCV) NS2 protein up-regulates HCV IRES-dependent translation and down-regulates NS5B RdRp activity. Arch. Virol. 2008, 153(11):1991-1997.
37. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5(9):558-567.
38. Tao W., Xu C., Ding Q., Li R., Xiang Y., Chung J., Zhong J. A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles. Virology 2009, 395(1):67-76.
39. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11(7):791-796.
40. Yang B., Guo M., Herman J.G., Clark D.P. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am. J. Pathol. 2003, 163(3):1101-1107.
41. Yang X., Lay F., Han H., Jones P.A. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol. Sci. 2010, 31(11):536-546.